These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8956684)

  • 81. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Clozapine decreases smoking in patients with chronic schizophrenia.
    McEvoy J; Freudenreich O; McGee M; VanderZwaag C; Levin E; Rose J
    Biol Psychiatry; 1995 Apr; 37(8):550-2. PubMed ID: 7619979
    [No Abstract]   [Full Text] [Related]  

  • 83. Beta-endorphin, vasoactive intestinal peptide and cholecystokinin in peripheral blood mononuclear cells from healthy subjects and from drug-free and haloperidol-treated schizophrenic patients.
    Panza G; Monzani E; Sacerdote P; Penati G; Panerai AE
    Acta Psychiatr Scand; 1992 Mar; 85(3):207-10. PubMed ID: 1561892
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Treatment of chronic schizophrenia with cyproheptadine.
    Silver H; Blacker M; Weller MP; Lerer B
    Biol Psychiatry; 1989 Feb; 25(4):502-4. PubMed ID: 2649160
    [No Abstract]   [Full Text] [Related]  

  • 85. Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration.
    Möller HJ; Kissling W; Lang C; Doerr P; Pirke KM; von Zerssen D
    Am J Psychiatry; 1982 Dec; 139(12):1571-5. PubMed ID: 7149056
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.
    Kane JM; Davis JM; Schooler N; Marder S; Casey D; Brauzer B; Mintz J; Conley R
    Am J Psychiatry; 2002 Apr; 159(4):554-60. PubMed ID: 11925292
    [TBL] [Abstract][Full Text] [Related]  

  • 87. SPECT studies of D2 occupancy in low-dose haloperidol treatment.
    Hirschowitz J; Hitzemann R; Vallabhajosula S
    Am J Psychiatry; 1997 May; 154(5):715-6. PubMed ID: 9137141
    [No Abstract]   [Full Text] [Related]  

  • 88. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
    Convit A; Volavka J; Czobor P; de Asis J; Evangelista C
    Am J Psychiatry; 1994 Jan; 151(1):49-56. PubMed ID: 8267134
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia.
    Ota KY; Kurland AA
    J Clin Pharmacol New Drugs; 1973; 13(2):99-110. PubMed ID: 4568299
    [No Abstract]   [Full Text] [Related]  

  • 91. Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate.
    Altamura AC; Tacchini GL; Maes M
    Eur Neuropsychopharmacol; 1995; 5 Suppl():55-8. PubMed ID: 8775759
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Neurological features, cognitive impairment and neuroleptic response in schizophrenic patients.
    Bartkó G; Frecska E; Zádor G; Herczeg I
    Schizophr Res; 1989; 2(3):311-3. PubMed ID: 2487171
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Behavioral considerations.
    Neborsky R; Janowsky D; Munson E; Depry D
    Arch Gen Psychiatry; 1981 Feb; 38(2):195-9. PubMed ID: 7011249
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Blink rate response to haloperidol as possible predictor of therapeutic outcome.
    Bartkó G; Herczeg I; Zádor G
    Biol Psychiatry; 1990 Jan; 27(1):113-5. PubMed ID: 2297547
    [No Abstract]   [Full Text] [Related]  

  • 95. Psychopharmacological study of schizophrenia--some ways out of an impasse. A case study with haloperidol.
    Singh MM
    Int Pharmacopsychiatry; 1973; 8(1):80-98. PubMed ID: 4595193
    [No Abstract]   [Full Text] [Related]  

  • 96. Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients.
    Davidson M; Harvey PD; Bergman RL; Powchik P; Kaminsky R; Losonczy MF; Davis KL
    Arch Gen Psychiatry; 1990 Feb; 47(2):190-1. PubMed ID: 2405808
    [No Abstract]   [Full Text] [Related]  

  • 97. Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid.
    Straw GM; Bigelow LB; Kirch DG
    J Clin Psychopharmacol; 1989 Apr; 9(2):130-2. PubMed ID: 2566628
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.
    Kelly MW; Perry PJ; Coryell WH; Miller DD; Arndt SV
    Psychopharmacology (Berl); 1990; 102(4):514-20. PubMed ID: 2096408
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.
    Reyntigens AJ; Heykants JJ; Woestenborghs RJ; Gelders YG; Aerts TJ
    Int Pharmacopsychiatry; 1982; 17(4):238-46. PubMed ID: 7185768
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effects of haloperidol decanoate on plasma homovanillic acid in chronic schizophrenic patients.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Lane HY; Jann MW
    Biol Psychiatry; 1993 Apr; 33(7):557-9. PubMed ID: 8513043
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.